Hims & Hers faces a lawsuit from the US Federal Trade Commission alleging unauthorized sharing of health data with advertisers and deceptive billing practices. The telehealth provider has denied all claims, labeling them as baseless. Shares of the company dropped roughly 12% following the announcement.
The US Federal Trade Commission (FTC) has initiated legal action against Hims & Hers, a major telehealth provider, centered on allegations of improper data sharing and questionable consumer billing practices. The regulator claims the company disclosed sensitive user health information to advertising platforms, including Meta Platforms and Snap, despite public commitments to maintain data privacy.
Billing and Cancellation Allegations
In addition to privacy concerns, the FTC lawsuit highlights issues regarding the company's subscription and billing model. The agency alleges that Hims & Hers charged users for prescription services before the completion of necessary consultations with healthcare providers. According to the complaint, customers were billed shortly after submitting initial intake forms without receiving medical assessments. The FTC also asserts that the company employed strategies designed to make it difficult for users to cancel their ongoing subscriptions.
Company Response and Market Impact
Following the filing, Hims & Hers publicly rejected the allegations. In a statement, the company described the lawsuit as baseless, arguing that the enforcement action was intended to generate headlines rather than provide legitimate consumer protection. The company maintains that its business practices remain compliant with regulatory standards.
Market participants reacted to the news with concern, leading to a decline of approximately 12% in the company's share price. Hims & Hers operates in several competitive healthcare segments, including treatments for hair loss, erectile dysfunction, and mental health. More recently, the company has expanded its focus to include weight-loss medications, a segment that has seen significant investment and consumer interest across the broader telehealth sector.
Investor Monitorables
For investors, the primary area of focus will be the progression of the legal proceedings. The outcome could potentially impact the company’s operating model, particularly regarding its customer acquisition and subscription retention tactics. Investors may also track future updates from the company regarding how these legal challenges might affect its growth trajectory in the weight-loss drug market, as well as any adjustments to its data privacy policies or billing procedures that may be required as the case unfolds.